指南与共识乳腺癌

乳腺癌新辅助化疗、内分泌治疗及靶向治疗:ASCO指南

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2021-01-28

ASCO专家组系统综述乳腺癌新辅助治疗文献,共41篇符合标准。推荐多学科团队管理,适用于炎性乳腺癌、残留病灶可能改变治疗者等;TNBC淋巴结阳性或≥T1c应接受蒽环联合紫杉方案,cT1a/T1bN0不常规新辅助;HR阳性/HER2阴性绝经后可用内分泌降期;HER2阳性淋巴结阳性或高危淋巴结阴性应新辅助联合抗HER2。

要点

  • 新辅助治疗应由多学科团队管理,适用人群包括炎性乳腺癌及残留病灶可能改变治疗者。
  • TNBC临床淋巴结阳性和/或≥T1c接受蒽环联合紫杉方案,cT1a/T1bN0不常规新辅助。
  • HER2阳性淋巴结阳性或高危淋巴结阴性应新辅助联合抗HER2,T1aN0/T1bN0不常规新辅助。

核心结论

  • 乳腺癌新辅助治疗应根据分子分型、分期和临床情况个体化选择,多学科团队共同管理。

研究设计与样本

  • ASCO召集专家组对乳腺癌新辅助治疗文献进行系统综述,共41篇文章符合纳入标准。

主要发现

  • TNBC临床淋巴结阳性和/或至少T1c应接受含蒽环和紫杉的方案,cT1a或cT1bN0不常规新辅助。
  • TNBC可考虑卡铂以提高病理完全缓解,但目前证据不足以支持在标准化疗中常规加免疫检查点抑制剂。
  • HR阳性/HER2阴性肿瘤在无需手术信息即可决策时可用新辅助化疗,绝经后患者可用内分泌治疗降期。
  • HER2阳性淋巴结阳性或高危淋巴结阴性应新辅助联合抗HER2治疗,T1aN0和T1bN0不常规新辅助。

关键数值与推荐

  • 肿瘤组织学、分级、分期及ER、PR、HER2表达应常规用于指导临床决策,其他标志物或基因组谱证据不足。
  • TNBC临床淋巴结阳性和/或至少T1c推荐含蒽环和紫杉方案;cT1a或cT1bN0不常规推荐新辅助治疗。
  • TNBC可提供卡铂以增加病理完全缓解;证据不足以支持加用免疫检查点抑制剂。
  • HER2阳性淋巴结阳性或高危淋巴结阴性推荐新辅助联合抗HER2治疗;T1aN0和T1bN0不常规推荐。

临床怎么用

  • 新辅助治疗决策应基于多学科团队评估,结合组织学、分级、分期和ER/PR/HER2状态。
  • 对TNBC和HER2阳性患者按分期和淋巴结状态选择是否新辅助及具体方案。
  • HR阳性/HER2阴性绝经后患者可考虑内分泌治疗降期;无需手术信息即可决策时可用新辅助化疗。

局限性

  • 证据不足以支持使用其他标志物或基因组谱指导新辅助治疗决策。
  • 目前证据不足以支持在TNBC标准化疗中常规加用免疫检查点抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended care options. RESULTS: A total of 41 articles met eligibility criteria and form the evidentiary basis for the guideline recommendations. RECOMMENDATIONS: Patients undergoing neoadjuvant therapy should be managed by a multidisciplinary care team. Appropriate candidates for neoadjuvant therapy include patients with inflammatory breast cancer and those in whom residual disease may prompt a change in therapy. Neoadjuvant therapy can also be used to reduce the extent of local therapy or reduce delays in initiating therapy. Although tumor histology, grade, stage, and estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) expression should routinely be used to guide clinical decisions, there is insufficient evidence to support the use of other markers or genomic profiles. Patients with triple-negative breast cancer (TNBC) who have clinically node-positive and/or at least T1c disease should be offered an anthracycline- and taxane-containing regimen; those with cT1a or cT1bN0 TNBC should not routinely be offered neoadjuvant therapy. Carboplatin may be offered to patients with TNBC to increase pathologic complete response. There is currently insufficient evidence to support adding immune checkpoint inhibitors to standard chemotherapy. In patients with hormone receptor (HR)-positive (HR-positive), HER2-negative tumors, neoadjuvant chemotherapy can be used when a treatment decision can be made without surgical information. Among postmenopausal patients with HR-positive, HER2-negative disease, hormone therapy can be used to downstage disease. Patients with node-positive or high-risk node-negative, HER2-positive disease should be offered neoadjuvant therapy in combination with anti-HER2-positive therapy. Patients with T1aN0 and T1bN0, HER2-positive disease should not be routinely offered neoadjuvant therapy.Additional information is available at www.asco.org/breast-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021. PMID: 33507815. doi:10.1200/JCO.20.03399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。